Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

LakeShore Biopharma Co., Ltd

$0.63

-0.16 (-20.62%)

Last traded Sep 19, 2025. This price is not current.

D 27Pipeline Score Richly Valued Biotech · Clinical
Market Cap
25.84 M
EPS
-
P/E Ratio
-
Value Trade
613.76 K
-26.24 %
Week
-20.64 %
1 Month
-32.58 %
3 Month
-71.24 %
6 Month
-99.34 %
5 Year
-99.34 %
All Time
Cash Data

  • Cash Position

    -

  • Monthly Burn

    -

  • Runway

    -

Overview
Volume
942.22 K
52 Week Range
0.57 - 8.60
% held by Insiders
82.69 %
% held by Institutions
6.24 %
Enterprise Value
68.60 M
Total Shares
41.21 M
Short %
0.24 %
Float Shares
4.96 M
Company Description

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
Phase 3 data readout example
Phase 3
—

Subscribe to access the data.

Vaccines
Infectious Diseases
Phase 3
—

Subscribe to access the data.

Vaccines
Infectious Diseases
Phase 3
—

Subscribe to access the data.

Vaccines
Infectious Diseases
Unlock Upcoming Catalyst data
Unlock the full Catalyst Timeline
Past FDA Catalysts & PDUFA Decisions
Date Drug Catalyst Stage Outcome Reaction Event Move % Best Trade %
—
Example Drug
Phase 3 data readout
Phase 3
—
–
0%
0%
—
Example Drug
Phase 3 data readout
Phase 3
—
–
0%
0%
—
Example Drug
Phase 3 data readout
Phase 3
—
–
0%
0%
Unlock Historical Catalyst data
Drug Pipeline Intelligence
D27
Pipeline Score
$1M
Pipeline Value
Richly Valued
Valuation Signal
3
Drugs Scored
0.0x
rNPV / MCap
Top 29%
Micro Cap
(rank 663 of 933)
Percentile Rank
LakeShore Biopharma Co., Ltd faces pipeline headwinds (27/100), with $236M risk-adjusted pipeline value, led by YS-0N-001 in Cancer (Phase 1).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
YS-0N-001
Monoclonal antibody		CancerPhase 1NCT031317659% $126M COMPLETED 31 - -Dec 16, 2019 -Dec 5, 2023
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
PIKA Rabies Vaccine
rabies virus infection
Phase 3
2024-04-09

RVNA seroconversion rate: twice that of the comparator by Day 7

Read More

YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine GAITHERSBURG, Md.

Read More
PIKA Rabies Vaccine
rabies virus infection
Phase 3
2024-04-09

RVNA seroconversion rate: twice that of the comparator by Day 7

Read More

YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine GAITHERSBURG, Md.

Read More
PIKA Rabies Vaccine
rabies virus infection
Phase 3
2024-04-09

RVNA seroconversion rate: twice that of the comparator by Day 7

Read More

YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine GAITHERSBURG, Md.

Read More
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in LSB
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
LSB Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How LSB ranks across every disease it competes in
Competitive Position is a premium feature
See how LSB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial